Background. The renoprotective effect of ACE inhibition in chronic renal disease is well established but the studies on effects of calcium antagonists on progression of renal disease and on proteinuria have given varying results.
Introduction
In chronic renal disease, renal function often continues to deteriorate even if the initiating insult is no longer present. Hypertension is one of the most prominent risk factors for the progression of renal disease and antihypertensive treatment is considered the cornerstone therapy for slowing the progression of chronic renal failure w1,2x. In experimental models of both nondiabetic and diabetic renal disease, antihypertensive treatment with ACE inhibitors caused an improvement in systemic and glomerular hypertension leading to a diminished albumin excretion and to a slower rate of progression of renal disease when compared with conventional antihypertensive treatment w3x. In 1986, it was shown that ACE inhibition had a beneficial effect on the progression of human diabetic nephropathy which was beyond that achieved by the blood pressure (BP) lowering effect per se w4x. This finding was later confirmed in a larger trial by Lewis et al. w5x who demonstrated a reduced risk of developing terminal renal failure after initiation of treatment with an ACE inhibitor in patients with type I diabetes and nephropathy. The mechanism of the renoprotective effect of ACE inhibition is not clear, but reduction in proteinuria via beneficial effects on glomerular haemodynamics anduor on the permeability and sizeselective function of the glomerulus may play an important role. This concept was further strengthened by data from the REIN study performed in patients with non-diabetic renal disease w6x. In this study, patients with proteinuria of P3 gu24 h experienced a clear reduction in proteinuria and in the rate of decline in glomerular filtration rate (GFR), which could not be explained by the improved BP control alone.
Calcium antagonists, in addition to their pronounced BP reduction, also have favourable effects on renal haemodynamics and renal tubular sodium reabsorption. As this class of drugs also has other properties that could contribute to their ability to protect the kidney w7x they have also been used with the intention to attenuate progression of renal disease. In some experimental studies, calcium antagonists have been shown to retard progression of renal insufficiency w8,9x but in others no beneficial effect has been demonstrated w10,11x.
Different types of calcium antagonists could act differently on the kidneys w12x. Studies with calcium antagonists of the non-dihydropyridine type have demonstrated a benefit on slowing progression of renal disease mirrored by reduction in proteinuria. However, calcium antagonists of the dihydropyridine type have had variable effects on renal disease progression and have often shown a lack of effect on proteinuria reduction. The effect of any putative renoprotective drug on proteinuria does, however, appear to be dependent on the BP reduction achieved w13x.
As there is evidence that angiotensin II is involved in the progression of renal disease it would make sense to combine ACE inhibitors, which diminish generation of angiotensin II, and calcium antagonists, which interfere with the renal response to angiotensin II on postreceptor level. We, therefore, decided to conduct a randomized prospective multi-centre study to compare the long-term renoprotective effect of the combination of the ACE inhibitor ramipril (R) and the calcium antagonist felodipine (F) and each drug per se in patients with non-diabetic renal disease. The antihypertensive treatment was titrated with the aim of achieving the same BP control in the three study groups during the study period.
Patients and methods
The protocol for this study was approved by the ethics committee of each of the five countries (UK, Germany, France, Israel, and Sweden) involved. The patients gave written informed consent.
Study objectives
The primary objective of the study was to compare the progression of renal impairment in patients with hypertension and reduced renal function during treatment with the combination of ramiprilqfelodipine (RqF) with that seen with either drug alone at the same achieved BP. A secondary objective was to assess the long-term effects of the three types of treatment on the degree of proteinuria in the patients.
Patients
Twenty-eight centres in Sweden, UK, Germany, France, and Israel took part in the study. Study participants were hypertensive patients of either sex, between 18 and 74 years old, with chronic nephropathy (nephrosclerosis, chronic glomerulonephritis, chronic pyelonephritis, or polycystic kidney disease) who had not received ACE inhibition or calcium antagonist treatment for at least 2 months. To enter the study supine diastolic blood pressure (DBP) (mean of two recordings) had to be P95 mmHg despite ongoing background therapy with a beta-blocker and a diuretic. This group of patients was at higher risk of progression because of uncontrolled BP on treatment with two antihypertensive agents. The beta-blocker and diuretic had to have been initiated at least 4 weeks before entry into the study. Chronic nephropathy was defined as a GFR value (Cr EDTA, inulin, or iohexol clearance) below the age-adjusted normal. Exclusion criteria were treatment with corticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressive drugs, or anti-epileptic drugs; acute myocardial infarction or stroke within 6 months before entry into the study; renal artery stenosis (as judged by investigator), diabetes mellitus; systemic disease; heart failure or angina pectoris requiring treatment other than short-acting glyceryl trinitrate; renal transplantation; nephrectomy; known bladder dysfunction; known intolerance to dihydropyridine calcium antagonists or ACE inhibitors.
Study design
After screening assessment, all eligible patients entered a 1-month run-in phase during which treatment was only with the background therapy with a beta-blocker and a diuretic (see Figure 1) .
The patients were asked to return to the hospital every second week for measurement of their BP. After 4 weeks, GFR, 24-h urinary albumin excretion, and routine biochemical tests were measured. Patients who had a supine DBP P95 mmHg and a GFR below the age-adjusted normal then entered the randomized open limb of the study.
The patients were randomly allocated to receive either the combination of RqF or either drug alone. The randomization code was prepared by Astra Hä ssle and the tablets were packed in blisters and supplied with a label showing the patients number. Each patient was given only the study medication carrying his or her number. The sequence of patients numbers was randomly assigned to each of the 28 study centres and the study medication randomly assigned to patient numbers in advance. Each centre received a set of randomization envelopes, one for each patient number.
R and F were available as 1.25, 2.5, 5 and 10 mg tablets. The tablets were packed in blisters labelled with dose level (low, medium-low, medium-high, high) in addition to the study code. The group randomized to receive the combination of RqF initially received 1.25 mg Fq1.25 mg R and the dose could be increased up to a maximum of 10q10 mg of each drug. The starting dose in the R and F groups was 2.5 mg once daily and the dose could be increased up to a maximum of 20 mg daily, respectively.
Each patient was examined by a physician at randomization and every 6 months thereafter. Six times during the first year and thereafter, four times a year the following measurements were made: BP and heart rate in the supine and standing positions, serum creatinine and electrolyte concentrations, liver enzymes, lipids, and uric acid.
Assessment of GFR and 24-h urinary excretion of albumin, sodium, and potassium were performed at months 3, 6, and 12 after randomization and every 12 months thereafter.
The study drug dose was increased every 2 weeks until DBP was reduced to below 90 mmHg. The doses of the background therapy (beta-blockerqdiuretic) could be increased if necessary to control the BP once the maximal tolerated dose level of study drugs had been achieved. Addition of antihypertensive therapies other than those of the defined background therapy and the study drugs was not allowed. All tablets should be taken once daily in the morning before visit to the clinic for study assessments.
Other than the choice of antihypertensive therapy, the routine care of the patients was determined by their responsible physician according to local practice. The responsible physician, however, was asked not to modify any aspect of the patient's care unless there was a clear clinical indication. Dietary intake with respect to protein content should remain as stable as possible throughout the entire study period. Patients were advised to adhere to modest sodium restriction and compliance was assessed by measurement of 24-h urinary sodium excretion.
Patients were withdrawn from the study if GFR fell below 10 mlumin, if goal BP DBP -90 mmHg could not be attained despite treatment with maximal beta-blocker, diuretic, and study drug doses or if unacceptable adverse events could not be relieved by dose reduction of antihypertensive treatment. The analysis of the study was performed according to the intention to treat principle.
Measurements of BP and renal function
BP and heart rate were measured after 5 min in the supine position and after 1 min in the standing position at every visit. The recordings were made in duplicate, with at least 1 min between the recordings. BP was recorded using a mercury sphygmomanometer and measured to the nearest 2 mmHg. Systolic blood pressure (SBP) was recorded as Korotkoff phase I and DBP as phase V. Heart rate was recorded by pulse palpations for 30 s immediately after the recording of the BP. The measurements were taken at the same time of the day for every visit.
GFR was assessed by measuring the clearance of iohexol, inulin, or of chromium-51 EDTA using the single injection clearance technique with blood sampling after 150, 195, and 240 min w14x. Each individual centre employed the same method to determine the GFR consistently in all patients throughout the duration of the study. All clearance measurements were corrected to 1.73 m 2 body surface area.
Statistics
Differences between baseline and last value were compared using the non-parametric Fisher's test for pair comparison. For two variables, GFR and serum creatinine the regression coefficient, i.e. the slope of a line that fits with all observed values in each patient, was calculated. Only patients with a follow-up time of at least 6 months were included in this analysis. In the analysis, GFR and serum creatinine were the dependent variables and the time from baseline the independent variable. In the statistical evaluation, the mean of all regression coefficients in each treatment group were compared. Differences between the groups with respect to regression coefficients were tested by means of Fisher's permutation test. Adjustment for multiple comparisons was performed by Bonferroni's inequality within the set of comparisons between groups.
Results
One hundred and sixty-five patients were randomized into the study and 158 had complete BP data at baseline and at follow-up. Demographic and clinical data at baseline are shown in Tables 1 and 2 and there was no significant difference between the three groups in any variable. The number of patients with glomerulonephritis, nephrosclerosis, polycystic kidney disease, and tubulo-interstitial nephritis are shown in Table 3 . Mean follow-up times and ranges were 1.83 (0.1-3.7), 1.52 (0.1-3.6), and 1.83 (0.3-3.8) years for the RqF, R, and F groups, respectively. The number of patients followed for P1 year were 44 in the RqF group, 37 in the R group, and 44 in the F group. Mean doses of medication at last visit were 5q5 mg for the combination of RqF, 10 mg for R alone, and 9 mg for F alone. The achieved sodium intake measured as urinary sodium excretion was 140 (113-230), 190 (138-220), and 170 (118-214) in the RqF, R, and F groups, respectively. They did not differ significantly from each other. The reduction in SBP and DBP (baseline mean of last three values) is shown in Table 4 . There was a significant decrease in SBP and DBP in all three groups (P-0.001). The reduction in SBP and DBP tended to be more pronounced in the RqF group compared with the group treated with R alone but the difference did not reach statistical significance (Ps0.10 for SBP). The attained BP (mean of the three last values) in the three groups are also shown in Table 3 . The attained SBP was significantly lower in the RqF group compared with the R group (P-0.05). The number of non-responders with respect to the BP goal (DBP-90 mmHg) were in the RqF, R, and F groups 14%, 40%, and 17%, respectively. There was a Values are median and 25th and 75th percentiles. Values are median and 25th and 75th percentiles. significant difference between the RqF group and the group that received R alone (P-0.05). Heart rate did not change during treatment in any of the groups. The urinary albumin excretion did not differ between the three groups at baseline ( Table 2) . As there was a large standard deviation of urine albumin relative to the mean, urine albumin was transformed to a normally distributed variable. In the statistical analysis of the transformed values, the urinary albumin excretion increased significantly during the treatment period in the F-group, median 25th and 75th percentile (0.137,À0.195 to 0.363, P-0.05) while it tended to decrease in the RqF (À0.03,À0.362 to 0.318) and R (À0.103,À0.336 to 0.150) groups. There was no significant difference between the groups in this respect.
The change from baseline to last visit is determined by only two observed values rather than the complete data set. Therefore, an analysis was performed which took account of all the measured values in each patient for GFR and serum creatinine. To do this a regression coefficient, i.e. the slope of a line that fits with the observed values in each patient, was calculated for these variables with time from baseline as independent variable. Only patients with a follow-up time of at least 6 months were included in this analysis. The statistical evaluation was based on the mean of all regression coefficients in each treatment group. Table 5 shows the median regression coefficients for GFR and 1userum creatinine for each treatment group. It demonstrates that the RqF group had a 40% slower rate of progression compared with each drug alone but the differences did not reach statistical significance (P)0.20 for both). It also shows that the RqF group had a tendency to a slower rate of progression of renal disease as measured by 1ucreatinine compared with the F group (Ps0.06) but not to the R group during the study period. A differentiation between the acute effects of the interventions on GFR and 1ucreatinine in the first few months vs the longer-term effects, was also performed. The acute effect was the difference between GFR or 1ucreatinine at baseline and the first post-randomization measurement (at 3 months). A significant acute reduction in GFR was seen in the R group (À3.2"7.0 mlumin, P-0.01) while no significant change was found in the F (q0.4"8.0 mlumin) and RqF (À0.7"6 mlumin) groups, respectively. No significant difference between the groups was found in this respect. The long-term effect was estimated by calculating the regression coefficient from 3 months to the end of the study. In Table 5 it is shown that with respect to this long-term effect the RqF group had a significantly slower rate of progression compared with the F group (P-0.05) but not to the R group (P)0.20).
There was no significant correlation between either changes in or attained SBP or DBP and the rate of progression of renal disease (P)0.10). Neither was there any significant correlation between changes in urinary albumin excretion and the rate of progression of renal disease (P)0.20). Table 6 shows the reasons for withdrawal from the study. Of note seven patients had to be withdrawn from the R group during the study because of uncontrolled hypertension, whereas no patient was Overall effect calculated from À3.2 (À6.8 to À0.4)*** À4.7 (À8.8 to À1.5)*** À4.8 (À8.1 to 0.8)*** baseline GFR (mluminuyear) 1ucreatinine (lummoluyear) 3 Values are median and the 25th to 75th percentile. For 1ucreatinine mean"SD is also given. Adjustment for multiple comparisons has been performed. *P-0.05. **P-0.01 compared with baseline. ***P-0.001 compared with baseline. withdrawn from treatment from the RqF group for this reason.
Discussion
The present study is the first to demonstrate a potential benefit for combination therapy with a long-acting ACE inhibitor, R and a calcium antagonist of the dihydropyridine type, such as F when used in addition to baseline therapy with beta-blockers and diuretics, in non-diabetic patients with progressive renal disease and hypertension. It was possible to use lower doses of each drug and still achieve a favourable result as regards reduction in BP, effect on proteinuria and progression. The combination therapy tended to lower the rate of progression of renal disease and no increase in albuminuria occurred.
As calcium antagonists have been found to produce acute increases in GFR and ACE inhibitors cause acute drops in GFR we also calculated a progression rate from 3 months onwards. Long-term progression rate calculated in this way was significantly slower in the group with combined treatment as compared with the F group. This beneficial effect of the calcium antagonist in combination with an ACE inhibitor is probably a result of improved BP control but specific effects of the drug could not be excluded. However, the small number of patients included in each study arm and the variable follow-up time of the patients limit the possibility to draw firm conclusions from the present study in this respect.
ACE inhibition has been shown to decrease proteinuria and the rate of progression in both diabetic and non-diabetic renal disease w5,6x. In 1997, a metaanalysis of patients with non-diabetic renal disease showed that ACE inhibitors were more effective than other antihypertensive agents in reducing the development of end-stage renal disease w14x. However, it was not possible to determine whether this beneficial effect was a result of the greater decline in BP seen with ACE inhibition or to some other effects of ACE inhibition. A more recent meta-analysis w15x concluded that the renal protective effect of antihypertensive regimens containing ACE inhibitors were better than those without ACE inhibitors even after accounting for their greater BP lowering effect. This effect was greatest in patients with proteinuria.
Administration of ACE inhibitors prevents the generation of angiotensin II, which normally acts on the renal microvasculature, especially the efferent arteriole causing vasocontriction. ACE inhibition would, therefore, decrease glomerular capillary pressure and thereby reduce the glomerular permeability to proteins, which are then filtered in lower amounts w16x. The ACE inhibitors may also confer their beneficial effects on the progression of renal disease by modulation of other processes independent of their ability to diminish glomerular hypertension w17x.
Calcium antagonists have also been reported to possess renoprotective effects in chronic renal disease w18x. This class of drug preferentially dilate the afferent arteriole causing if anything an increase in glomerular capillary pressure, suggesting their renoprotective effect is independent of changes in glomerular capillary pressure. Calcium antagonists, however, have other beneficial effects that may contribute to their ability to protect the kidney under various circumstances. For example, they may diminish injury by retarding renal growth w19x, improve glomerular size selectivity w20x, attenuate mesangial entrapment of macro-molecules w21x, and counteract or attenuate the mitogenic effects of various cytokines and growth factors w22x.
Experimental data on the effects of calcium antagonists has shown variable results. In one experimental model, nifedipine was as good as enalapril in retarding the progression of renal disease w7x although in other models dihydropyridines had no effect w9x. The balance between the loss of intrarenal autoregulation, which occurs with calcium antagonists, and the magnitude of the BP reduction achieved may be important in determining the renal outcome following treatment with these drugs. As long as the BP is well controlled any increase in intraglomerular pressure caused by the decreased afferent arteriolar tone may be offset w23x.
There are only a few human studies comparing the renoprotective effects of calcium antagonists and ACE inhibitors. Zuchelli et al. w24x in a prospective randomized controlled trial in non-diabetic renal disease compared the effects of captopril and nifedipine on hypertension and the progression of renal insufficiency. The rate of progression of renal disease assessed as 1ucreatinine vs time, creatinine clearance vs Table 6 . Reasons for withdrawal from treatment in patients treated with the combination of ramipril and felodipine ER and each drug alone Ramiprilqfelodipine ns51
Ramipril ns53
Felodipine ns54 time and DTPA clearance vs time was retarded to a similar degree in both groups suggesting each drug was equally renoprotective. Concern has, however, been raised regarding this study as very few patients completed the 3-year study period. The data from the present study, having a mean observation time close to 2 years, do support the study by Zuchelli et al. w24x. In our study there was no difference in the rate of progression of renal disease between the ACE inhibitor and the calcium antagonist groups despite the fact that the latter significantly increased albuminuria. A similar pattern of response was demonstrated by Rossing et al. w25x in patients with diabetic nephropathy. They compared the ACE inhibitor lisinopril with the long-acting dihydropyridine calcium antagonist nisoldipine with respect to proteinuria and decline in GFR. After 1 year there was a clear dissociation between the antiproteinuric effect and the effect on GFR. Albuminuria decreased in the lisinopril but not in the nisoldipine group, while the GFR decrease was less pronounced in the nisoldipine group. Recently the 4-year data from this study has been published demonstrating persistence of the previously reported pattern w26x.
Most patients with renal insufficiency and hypertension need more than one antihypertensive drug to achieve BP control w27x. The data from the present study argue in favour of the combination of an ACE inhibitor and a long-acting dihydropyridine calcium antagonist as a promising renoprotective treatment in this group of patients. The combination therapy allowed the use of lower doses of each drug and still there was a high proportion of responders with respect to the target BP, no increase in proteinuria, and a tendency to a slower progression of the renal disease. In addition, no patient from the group receiving the combination treatment was withdrawn from treatment for failure to control the BP compared with seven patients in the group with R alone. There was no significant difference in the reduction of SBP and DBP between the three treatment groups in our study, but we, however, achieved a significantly lower SBP in the group with combination treatment as compared with the group treated with R alone. This difference may have contributed to the effects observed.
Only one clinical study using this combination therapy has been published previously w28x. This demonstrated that in patients with type II diabetes and nephropathy, BP could be lowered to a similar extent with verapamil or lisinopril in monotherapy or the combination of the two in reduced doses during 4 years. However, combination therapy lowered proteinuria to a greater extent than either drug alone.
In conclusion, the combination of the ACE inhibitor R and the calcium antagonist F in reduced doses used in addition to baseline therapy with beta-blockers and diuretics tended to cause better BP lowering response as either drug alone in patients with non-diabetic renal disease. In addition, the group with the combination therapy showed a tendency to a slower progression of the renal disease and a similar urinary albumin excretion as the R group alone. These data suggest that such combination therapy may be an efficient therapeutic strategy for achieving good BP control, and retarding the progression of non-diabetic chronic renal failure.
